Ontology highlight
ABSTRACT:
SUBMITTER: Sharma MR
PROVIDER: S-EPMC3328614 | biostudies-literature | 2012 Apr
REPOSITORIES: biostudies-literature
Sharma Manish R MR Karrison Theodore G TG Jin Yuyan Y Bies Robert R RR Maitland Michael L ML Stadler Walter M WM Ratain Mark J MJ
Clinical cancer research : an official journal of the American Association for Cancer Research 20120127 8
<h4>Purpose</h4>The best phase II design and endpoint for growth inhibitory agents is controversial. We simulated phase II trials by resampling patients from a positive (sorafenib vs. placebo; TARGET) and a negative (AE941 vs. placebo) phase III trial in metastatic renal cancer to compare the ability of various designs and endpoints to predict the known results.<h4>Experimental design</h4>A total of 770 and 259 patients from TARGET and the AE 941 trial, respectively, were resampled (5,000 replic ...[more]